PMID- 32569187
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Erlotinib plus tivantinib versus erlotinib alone in patients with previously 
      treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on 
      randomized controlled trials.
PG  - e20596
LID - 10.1097/MD.0000000000020596 [doi]
LID - e20596
AB  - BACKGROUND: Whether erlotinib plus tivantinib (ET) can achieve better clinical 
      benefits than erlotinib plus placebo (EP) among participants with previously 
      treated advanced non-small-cell lung cancer (NSCLC) is still disputed. We 
      conducted a meta-analysis to evaluate the anticancer efficacy and safety of both 
      regimens. MATERIALS AND METHODS: We searched for pertinent trials at PubMed, 
      ScienceDirect, The Cochrane Library, Scopus, Ovid MEDLINE, Embase, Web of 
      Science, and Google Scholar. Endpoints mainly included progression-free survival 
      (PFS), overall survival (OS), objective response rate (ORR), disease control rate 
      (DCR), and adverse events (AEs). RESULTS: We included 1522 patients who 
      previously received >/=1 systemic anti-cancer regimen that included platinum-based 
      chemotherapy. Although ET failed to improve OS (hazard ratio [HR] = 0.91, 95% 
      confidence interval [CI]: 0.75-1.10, P = .35), the ET group had better PFS 
      (HR = 0.73, 95% CI: 0.67-0.80, P < .00001), higher ORR (HR = 1.50, 95% CI: 
      1.06-2.12, P = .02), and better DCR (HR = 1.38, 95% CI: 1.20-1.59, P < .00001). 
      Our subanalysis suggested that the ET group may have had better OS among patients 
      with high Mesenchymal to epithelial transition factor (MET) expression 
      (HR = 0.76, 95% CI: 0.58-0.99, P = .04) and good VeriStrat (HR = 0.88, 95% CI: 
      0.83-0.93, P < .0001). AEs were roughly similar except for specific hematological 
      toxicities: more neutropenia and febrile neutropenia were observed in the ET 
      group, both of which should not be overlooked. CONCLUSIONS: ET appears to be 
      superior to EP due to better PFS and higher response rates, especially for 
      patients with high MET expression and good VeriStrat. The greater hematological 
      toxicity in the ET regimen is non-negligible.
FAU - Deng, Huan
AU  - Deng H
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
AD  - Jiangxi Medical College, Nanchang University.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
AD  - Jiangxi Medical College, Nanchang University.
FAU - Chen, Xinling
AU  - Chen X
AD  - Jiangxi Medical College, Nanchang University.
AD  - Department of Oncology, The second affiliated hospital of Nanchang University, 
      Nanchang, China.
FAU - Zhang, Shujuan
AU  - Zhang S
AD  - Jiangxi Medical College, Nanchang University.
AD  - Department of Oncology, The second affiliated hospital of Nanchang University, 
      Nanchang, China.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Oncology, The second affiliated hospital of Nanchang University, 
      Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (ARQ 197)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyrrolidinones)
RN  - 0 (Quinolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Erlotinib Hydrochloride/*administration & dosage/adverse effects
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Progression-Free Survival
MH  - Pyrrolidinones/*administration & dosage/adverse effects
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
PMC - PMC7313549
COIS- The authors report no conflicts of interest.
EDAT- 2020/06/23 06:00
MHDA- 2020/07/03 06:00
PMCR- 2020/06/19
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/06/19 00:00 [pmc-release]
AID - 00005792-202006190-00035 [pii]
AID - MD-D-19-07769 [pii]
AID - 10.1097/MD.0000000000020596 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20596. doi: 
      10.1097/MD.0000000000020596.